ArticlePloS one2016
High-Dimensional Analysis of Acute Myeloid Leukemia Reveals Phenotypic Changes in Persistent Cells during Induction Therapy.
Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 47 citations in OpenAlex.
- Mitochondrial potential reflects T cell fitness and function during cancer immunotherapy.Journal of immunology (Baltimore, Md. : 1950) · 2026Article
- Discovery of natural products that modulate signaling in patient-derived cells.RSC chemical biology · 2026Article
- Clustering Algorithm-Driven Detection of TRBC1-Restricted Clonal T-Cell Populations Produces Better Results than Manual Gating Analysis.International journal of molecular sciences · 2024Article
- A multicenter phase Ib trial of the histone deacetylase inhibitor entinostat in combination with pembrolizumab in patients with myelodysplastic syndromes/neoplasms or acute myeloid leukemia refractory to hypomethylating agents.Annals of hematology · 2024Article
- Single-cell profiling of the antigen-specific response to BNT162b2 SARS-CoV-2 RNA vaccine.Nature communications · 2022Article
- Cancer progression as a learning process.iScience · 2022Review
- Alignment of single-cell trajectories by tuMap enables high-resolution quantitative comparison of cancer samples.Cell systems · 2022Article
- Review
- Article
- Identification of ALP+/CD73+ defining markers for enhanced osteogenic potential in human adipose-derived mesenchymal stromal cells by mass cytometry.Stem cell research & therapy · 2021Article
- The Application of Single-Cell Technologies in Cardiovascular Research.Frontiers in cell and developmental biology · 2021Review
- Mass Cytometry in Hematologic Malignancies: Research Highlights and Potential Clinical Applications.Frontiers in oncology · 2021Review
- Unsupervised machine learning reveals key immune cell subsets in COVID-19, rhinovirus infection, and cancer therapy.bioRxiv : the preprint server for biology · 2020Article
- CD28 costimulation drives tumor-infiltrating T cell glycolysis to promote inflammation.JCI insight · 2020Article
- A Cancer Biologist's Primer on Machine Learning Applications in High-Dimensional Cytometry.Cytometry. Part A : the journal of the International Society for Analytical Cytology · 2020Review
- Is Hematopoietic Stem Cell Transplantation Required to Unleash the Full Potential of Immunotherapy in Acute Myeloid Leukemia?Journal of clinical medicine · 2020Review
- Early response evaluation in AML using mass cytometry.HemaSphere · 2019Article
- Clinical Proteomics for Post-Hematopoeitic Stem Cell Transplantation Outcomes.Proteomics. Clinical applications · 2019Review
- Computational Immune Monitoring Reveals Abnormal Double-Negative T Cells Present across Human Tumor Types.Cancer immunology research · 2019Article
- Transcriptomic Analysis Identifies RNA Binding Proteins as Putative Regulators of Myelopoiesis and Leukemia.Frontiers in oncology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
The plasticity of AML drives poor clinical outcomes and confounds its longitudinal detection. However, the immediate impact of treatment on the leukemic and non-leukemic cells of the bone marrow and blood remains relatively understudied. Here, we conducted a pilot study of high dimensional longitudinal monitoring of immunophenotype in AML. To characterize changes in cell phenotype before, during, and immediately after induction treatment, we developed a 27-antibody panel for mass cytometry focused on surface diagnostic markers and applied it to 46 samples of blood or bone marrow tissue collected over time from 5 AML patients. Central goals were to determine whether changes in AML phenotype would be captured effectively by cytomic tools and to implement methods for describing the evolving phenotypes of AML cell subsets. Mass cytometry data were analyzed using established computational techniques. Within this pilot study, longitudinal immune monitoring with mass cytometry revealed fundamental changes in leukemia phenotypes that occurred over time during and after induction in the refractory disease setting. Persisting AML blasts became more phenotypically distinct from stem and progenitor cells due to expression of novel marker patterns that differed from pre-treatment AML cells and from all cell types observed in healthy bone marrow. This pilot study of single cell immune monitoring in AML represents a powerful tool for precision characterization and targeting of resistant disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.